VVOS News & Events

Reports Q1 revenue $5.14M, consensus $4.35M. Kirk Huntsman, Vivos' chairman and CEO, stated "Our significant revenue increase year over year and quarter over quarter confirms what we emphatically stated when we reported our 2025 year end results last month: that the fourth quarter of 2025 was not fully indicative of our overall growth trajectory, which remains strong and is accelerating here in the second quarter. Our June 2025 acquisition of SCN and business model pivot continues to drive patient volume and top-line revenue, and we are working hard to increase the daily productivity of SCN doctors and insurance reimbursement. Importantly, and as expected, we are seeing a very significant reduction in customer acquisition costs. So, our goal is continued integration of, and growth from, SCN and other medical provider collaborations, and our current results demonstrate that this is achievable going forward. Meanwhile, we have implemented significant cost savings measures, and have simultaneously been working to secure new funding to meet our operating needs and to restructure our debt in order to improve our stockholders' equity and reduce cash burn, all with the goal of getting us to cash flow positive operations as soon as possible."

Vivos Therapeutics announced that an a recent published study supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea, or OSA, in adults and children. Vivos CARE devices have been cleared by the FDA for adult patients diagnosed with mild, moderate and severe OSA and moderate-to-severe OSA in children ages 6 to 17. Many Vivos patients finish treatment in less than 12 months with little or no remaining OSA symptoms. The OSA group exhibited significantly narrower transverse intermolar distance and higher palatal height compared to the control group. Linear regression analysis demonstrated a strong association between these two key craniofacial parameters and OSA severity, as measured by the industry standard measure AHI. These results held true across all demographics.